Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma |
Protocole ID | InMIND (INCMOR 0208-301) |
ClinicalTrials.gov ID | NCT04680052 |
Cancer Type(s) | Non-Hodgkin's Lymphoma |
Phase | Phase III |
Stage | Indolent Lymphoma |
Study Type | Clinical |
Drug | Tafasitamab + Lénalidomide et Rituximab comparé à placebo + Lénalidomide et Rituximab |
Institution |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4 |
City | |
Principal Investigator |
Dr. Isabelle Fleury |
Coordinator |
Nawel Mechtouf 514-252-3400 poste 4681 |
Status | Recruiting |
Activation Date | |
Eligibility Criteria |
|
Exclusion Criteria |
|